Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude sur le Buntanetap chez des participants atteints de la maladie de Parkinson

28 octobre 2026 mis à jour par: Annovis Bio Inc.

Un essai clinique ouvert évaluant la sécurité à long terme du buntanetap dans le traitement des participants atteints de la maladie de Parkinson

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Aperçu de l'étude

Statut

Recrutement

Intervention / Traitement

Description détaillée

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.

Type d'étude

Interventionnel

Inscription (Estimé)

500

Phase

  • Phase 2
  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Alabama
      • Birmingham, Alabama, États-Unis, 35233
        • Recrutement
        • University of Alabama at Birmingham
        • Contact:
        • Chercheur principal:
          • Natividad Stover, M.D.
    • Arizona
      • Sun City, Arizona, États-Unis, 85351
        • Recrutement
        • Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
        • Chercheur principal:
          • Sara Dhanani, M.D.
        • Contact:
    • California
      • Fountain Valley, California, États-Unis, 92708
        • Recrutement
        • Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
        • Chercheur principal:
          • Daniel Truong, M.D.
        • Contact:
          • Evan Moreno-Davis
          • Numéro de téléphone: 714-378-5074
          • E-mail: evan@pmdi.org
    • Colorado
      • Englewood, Colorado, États-Unis, 80113
        • Recrutement
        • Cenexel Rocky Mountain Clinical Research
        • Contact:
        • Chercheur principal:
          • Meagen Salinas, M.D.
    • Connecticut
      • Stamford, Connecticut, États-Unis, 06824
        • Recrutement
        • New England Institute for Clinical Research (Ki Health Partners)
        • Contact:
        • Chercheur principal:
          • Peter McAllister, M.D.
    • Florida
      • Aventura, Florida, États-Unis, 33180
        • Recrutement
        • First Choice Neurology - Aventura Neurologic Associates
        • Chercheur principal:
          • Jonathan Cross, M.D.
        • Contact:
      • Daytona Beach, Florida, États-Unis, 32117
        • Recrutement
        • Arrow Clinical Trials
        • Contact:
        • Chercheur principal:
          • David Billmeier, M.D.
      • DeLand, Florida, États-Unis, 32720
        • Recrutement
        • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
        • Chercheur principal:
          • Bruce Rankin, D.O.
        • Contact:
      • Miami, Florida, États-Unis, 33172
      • Miami, Florida, États-Unis, 33015
        • Pas encore de recrutement
        • Ezy Medical Research Co.
        • Contact:
      • Ocala, Florida, États-Unis, 34470
        • Recrutement
        • Renstar Medical Research
        • Chercheur principal:
          • Annette Nieves, M.D.
        • Contact:
      • Tampa, Florida, États-Unis, 33613
        • Recrutement
        • University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
        • Contact:
        • Chercheur principal:
          • Robert Hauser, M.D., MBA
      • Winter Park, Florida, États-Unis, 32789
        • Recrutement
        • Conquest Research
        • Contact:
        • Chercheur principal:
          • Rekha Gandhi, M.D.
    • Georgia
      • Decatur, Georgia, États-Unis, 30030
        • Recrutement
        • iResearch Atlanta
        • Contact:
        • Chercheur principal:
          • Kimball Johnson, M.D.
    • Indiana
      • Indianapolis, Indiana, États-Unis, 46256
        • Recrutement
        • Josephson Wallack Munshower Neurology, P.C.
        • Chercheur principal:
          • Kristi George, M.D.
        • Contact:
    • Kansas
      • Kansas City, Kansas, États-Unis, 66160
        • Recrutement
        • University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
        • Contact:
        • Chercheur principal:
          • Rajesh Pahwa, M.D.
    • Michigan
      • Farmington Hills, Michigan, États-Unis, 48334
        • Recrutement
        • Quest Research Institute
        • Chercheur principal:
          • Aaron Ellenbogen, D.O.
        • Contact:
    • New York
      • New York, New York, États-Unis, 10019
        • Recrutement
        • Mount Sinai Hospital
        • Chercheur principal:
          • Joohi Jimenez-Shahed, M.D.
        • Contact:
    • North Carolina
      • Durham, North Carolina, États-Unis, 27710
        • Recrutement
        • Duke Department of Neurosurgery
        • Chercheur principal:
          • Kyle Mitchell, M.D.
        • Contact:
    • Ohio
      • Columbus, Ohio, États-Unis, 43210
        • Recrutement
        • The Ohio State University Wexner Medical Center
        • Chercheur principal:
          • Zachary Jordan, M.D.
        • Contact:
    • Oklahoma
      • Tulsa, Oklahoma, États-Unis, 74136
        • Recrutement
        • The Movement Disorder Clinic of Oklahoma
        • Contact:
        • Chercheur principal:
          • Kevin Klos, M.D.
    • Pennsylvania
      • Willow Grove, Pennsylvania, États-Unis, 19090
        • Recrutement
        • Abington Neurology
        • Chercheur principal:
          • David Weisman, M.D.
        • Contact:
    • South Carolina
      • Charleston, South Carolina, États-Unis, 29401
        • Recrutement
        • Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
        • Contact:
        • Chercheur principal:
          • Vanessa Hinson, M.D., PhD
    • Tennessee
      • Cordova, Tennessee, États-Unis, 38018
        • Recrutement
        • Neurology Clinic, P.C.
        • Contact:
        • Chercheur principal:
          • Kendrick Henderson, M.D.
      • Memphis, Tennessee, États-Unis, 38157
        • Recrutement
        • Veracity Neuroscience LLC
        • Contact:
        • Chercheur principal:
          • Mark LeDoux, M.D., PhD
    • Texas
      • Round Rock, Texas, États-Unis, 78681
        • Recrutement
        • Central Texas Neurology
        • Contact:
        • Chercheur principal:
          • Elizabeth Peckham, M.D.
    • Virginia
      • Charlottesville, Virginia, États-Unis, 22903
        • Recrutement
        • University of Virginia Health System (UVAHS) - Adult Neurology Clinic
        • Chercheur principal:
          • Binit Shah, M.D.
        • Contact:
    • Washington
      • Spokane, Washington, États-Unis, 99202
        • Recrutement
        • Inland Northwest Research
        • Chercheur principal:
          • Jason Aldred, M.D.
        • Contact:
    • Wisconsin
      • Milwaukee, Wisconsin, États-Unis, 53226
        • Recrutement
        • Medical College of Wisconsin
        • Contact:
          • Shelby Schold
          • Numéro de téléphone: 414-955-0698
          • E-mail: sschold@mcw.edu
        • Chercheur principal:
          • Karen Blindauer, M.D.

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

40 ans à 85 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and

    a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.

    b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.

    i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.

  2. Have a support person who will accompany the participant on study visits at designated times.

  3. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    3. Intrauterine device (IUD),

    4. Intrauterine hormone-releasing system (IUS),

    5. Bilateral tubal occlusion,

    6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),

    7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54

  4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    3. IUD,
    4. IUS,
    5. Bilateral tubal occlusion.
  5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.

  6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

    1. Standard of care anti-parkinsonian medication,
    2. Cholinesterase inhibitors and/or memantine medication,
    3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
    4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,
  7. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  8. Good general health with no disease expected to interfere with the study.

Exclusion Criteria:

  1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).

  2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.

  5. Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54

  6. Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.

  7. Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).

  8. Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.

  9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.

  12. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  13. A learning disability or developmental delay.

  14. Participants whom the site PI deems to be otherwise ineligible.

  15. A known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified microcrystalline cellulose
    • Dibasic calcium phosphate dihydrate
    • Mannitol
    • Stearic acid
    • Hypromellose (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  16. Is currently pregnant, breast-feeding, and/or lactating.

  17. Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Cohort 1 - buntanetap

Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun

buntanetap capsules 30 mg by mouth daily

Expérimental: Cohort 2 - buntanetap

Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment.

buntanetap capsules 30 mg by mouth daily

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Safety of buntanetap
Délai: 36-months of treatment

Safety assessments of participants with PD receiving treatment with buntanetap

36-months of treatment
Adverse Events (AE)
Délai: 36-months of treatment

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

36-months of treatment
Treatment Emergent Adverse Events (TEAE)
Délai: 36-months of treatment

TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state

36-months of treatment
Serious Adverse Events (SAE)
Délai: 36-months of treatment

SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly

36-months of treatment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Laurie Sanders, Ph.D., Duke Clinical Research Institute

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

9 janvier 2026

Achèvement primaire (Estimé)

1 septembre 2029

Achèvement de l'étude (Estimé)

1 novembre 2029

Dates d'inscription aux études

Première soumission

26 novembre 2025

Première soumission répondant aux critères de contrôle qualité

9 décembre 2025

Première publication (Réel)

16 décembre 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

30 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

28 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner